2025-09-06 - Analysis Report
Okay, here's a comprehensive analysis of Schrodinger Inc. (SDGR) based on the information you provided.  The report is structured to first present key numbers, followed by analysis and context.

## Schrodinger Inc. (SDGR) Stock Analysis

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

### 1. Performance Analysis

*   **Cumulative Return:**
    *   SDGR: -54.65%
    *   S&P 500 (VOO): 57.42%
    *   **Difference:** -112.07% (SDGR significantly underperformed the S&P 500).

*   **Disparity Analysis:**
    *   Max Disparity: 66.2
    *   Min Disparity: -112.7
    *   Current Disparity: -110.0
    *   Relative Disparity: 1.5
    *   This indicates SDGR is near its historical low relative to the S&P 500.
*   **Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2020-2022  | -74.0%  | 68.9% | -89.0%  | -0.1  | 1.4    |
| 2021-2023  | -65.0%  | 68.9% | -83.0%  | -0.0  | 2.6    |
| 2022-2024  | 8.0%   | 72.4% | -17.0%  | -0.0  | 1.4    |
| 2023-2025  | -1.0%  | 74.0% | -54.0%  | -0.0  | 1.4    |

**Analysis:**

*   **Significant Underperformance:** SDGR has significantly underperformed the S&P 500, with a massive difference in cumulative returns.
*   **High Volatility:** The MDD values are very high, indicating high volatility and significant drawdowns.
*   **Negative Alpha & Beta:** The negative Alpha values suggest that the stock has underperformed relative to its risk-adjusted expected return. Beta values close to zero indicate very low correlation with the overall market. This suggests the stock's price movements are not closely tied to the S&P 500.

### 2. Recent Price Action

*   **Current Price:** $19.13
*   **Previous Close:** $18.97
*   **Change:** +$0.84
*   **5-day Moving Average:** 19.202
*   **20-day Moving Average:** 19.44
*   **60-day Moving Average:** 20.6147

**Analysis:**

*   **Slight Rebound:**  The price is slightly above the previous close, indicating a small positive change.
*   **Moving Averages:** The current price is below all moving averages, suggesting a short-term downtrend. The 5-day moving average is closest to the current price, while the 60-day moving average is the furthest, indicating that the longer-term trend is more bearish.

### 3. Technical Indicators and Outlook

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 47.39 (Neutral)
*   **PPO:** 0.0483
*   **Hybrid Signal:** "cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)"
*   **Recent (20-day) Relative Disparity Change:** +1.5 (Short-term increase)
*   **Expected Return (%):** -3803.1% (Significant underperformance vs S&P 500 over the long term)

**Analysis:**

*   **MRI:** The MRI indicates a low-risk environment, which is a positive signal.
*   **RSI:** The RSI is near 50, which means neutral.
*   **PPO:** The PPO value indicates the stock price is neither overbought nor oversold.
*   **Hybrid Signal:** Cautious buy signal, but still recommends deploying cash, suggesting the system sees some potential upside despite the risks. The small number of shares to buy (2) emphasizes the caution.
*   **Recent Disparity Change:** The positive change in relative disparity suggests a slight improvement in performance relative to the S&P 500 in the short term.
*   **Expected Return:** The extremely negative expected return is alarming. It suggests the model anticipates significant underperformance relative to the S&P 500 in the long term. This could be due to various factors, including the company's financial health, industry outlook, and competitive landscape.
*   **Price Change Impact:** The recent price change of +$0.84 is a positive sign, but it's important to consider whether this is a temporary fluctuation or the start of a more sustained uptrend. The fact that the price has risen after recent news (discussed below) could be a sign that investors are reacting positively to the company's announcements.

### 4. Recent News & Significant Events

*   **2025-08-27:** Schrödinger to Present at Morgan Stanley Global Healthcare Conference.
*   **2025-08-15:** Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
*   **2025-08-14:** Schrödinger Announces Discontinuation of SGR-2921 Program.
*   **2025-08-06:** Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates.
*   **2025-08-06:** Schrödinger Reports Second Quarter 2025 Financial Results.

**Analysis:**

*   **Mixed Signals:** The news is a mix of positive and negative. Presenting at a conference is generally positive, and beating revenue estimates is good. However, reporting a loss and discontinuing a program are negative.
*   **Program Discontinuation:** The discontinuation of SGR-2921 is a significant event.  It suggests the company is streamlining its pipeline, which could be seen as a positive if the program was not performing well, but also raises questions about future growth.

### 4-2. Analyst Opinions

*   **Consensus:** No key consensus reported.
*   **Mean Rating:**  - (No rating provided)
*   **Number of Opinions:** 10
*   **Target Price:**
    *   Average: $27.30
    *   High: $33.00
    *   Low: $19.00
*   **Recent Rating Changes:**  None specified.

**Analysis:**

*   **Upside Potential:**  The average target price of $27.30 is significantly higher than the current price of $19.13, suggesting substantial upside potential according to analysts.  However, the range is wide (19.00 - 33.00), indicating some uncertainty among analysts.
*   **Missing Information:** The missing consensus and rating make it difficult to fully assess analyst sentiment.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출      |
|------------|--------|-----------|
| 2025-08-06 | -0.59  | 0.05 B$   |
| 2025-05-07 | -0.82  | 0.06 B$   |
| 2024-11-12 | -0.52  | 0.04 B$   |
| 2024-07-31 | -0.74  | 0.05 B$   |
| 2025-08-06 | -0.74  | 0.05 B$   |

**Analysis:**

*   **Consistent Losses:** SDGR has consistently reported losses per share (EPS) over the past five quarters.
*   **Relatively Stable Revenue:** Revenue has remained relatively stable, fluctuating between $0.04B and $0.06B.
*   **Recent Improvement:** The most recent EPS (-0.59) is an improvement compared to the previous quarter (-0.82).

### 6. Financial Information

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|----------------|
| 2025-06-30   | $0.05B    | 47.77%         |
| 2025-03-31   | $0.06B    | 52.26%         |
| 2024-12-31   | $0.09B    | 72.61%         |
| 2024-09-30   | $0.04B    | 50.24%         |
| 2024-06-30   | $0.05B    | 66.20%         |

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-06-30   | $0.34B    | -12.59%  |
| 2025-03-31   | $0.37B    | -16.01%  |
| 2024-12-31   | $0.42B    | -9.54%   |
| 2024-09-30   | $0.45B    | -8.49%   |
| 2024-06-30   | $0.47B    | -11.40%  |

**Analysis:**

*   **Profit Margin Fluctuation:** Profit margins have fluctuated significantly, with a high of 72.61% in Q4 2024 and a low of 47.77% in the most recent quarter.
*   **Declining Equity:** Equity has been declining steadily, indicating a potential strain on the company's financial health.
*   **Negative ROE:** The negative return on equity (ROE) values are concerning and indicate that the company is not effectively generating profits from its equity.

### 7. Overall Analysis and Conclusion

Schrodinger Inc. (SDGR) presents a mixed picture.

*   **Negative Factors:** The company has significantly underperformed the S&P 500, is experiencing consistent losses, has negative ROE, and declining equity. The technical indicators are not strongly bullish, and the expected return is extremely negative.
*   **Positive Factors:** Revenue has been relatively stable, and profit margins are relatively high. Analysts see significant upside potential (though with a wide range), and the MRI suggests a low-risk environment. The company is presenting at a major healthcare conference.
*   **Critical Considerations:** The discontinuation of the SGR-2921 program is a significant event that investors should carefully consider. It could impact the company's future growth prospects.

**Recommendation:**

Based on the data provided, a **cautious approach** is warranted. While analysts see upside potential, the numerous negative factors and the extremely negative expected return suggest significant risks. Investors should conduct thorough due diligence, carefully consider their risk tolerance, and monitor the company's progress closely before making any investment decisions.  It is also important to look into *why* the model is predicting such a negative expected return, as this could highlight underlying issues not immediately apparent from the other data.
